10x Genomics Q3 revenue $151.7M (-1% YoY); cuts FY2024 revenue guidance to $595-605M

10x Genomics, Inc.

2024-Q3 EPS reported -$1.11 revenue$445,764,000

Revenue $151.7M, down 1% YoY; net loss improved to $35.8M from $93.0M.
FY2024 revenue guidance lowered to $595-605M from prior $640-660M (3% decline YoY midpoint).
CEO cites greater-than-anticipated disruption from sales restructuring and cautious spending.
Board member Mathai Mammen resigned effective Oct 24, 2024 due to professional time commitments.
Launched GEM-X Flex, GEM-X Universal Multiplex, and Chromium Xo instruments.

item 2.02 item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Mathai Mammen

Member of the Board of Directors

TXG · 10x Genomics, Inc.

Effective: 2024-10-24
Filed: October 29, 2024, 7:59 PM ET

On October 24, 2024, Mathai Mammen informed the Company of his decision to resign as a member of the Board of Directors

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Mathai Mammen resigned as Member of the Board of Directors at 10x Genomics, Inc..

Action: resigned
Role: Member of the Board of Directors

Exact text from the filing

On October 24, 2024, Mathai Mammen informed the Company of his decision to resign as a member of the Board of Directors

View on SEC.gov

10x Genomics, Inc. filing history →

Source: SEC EDGAR

accession 0001770787-24-000071

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.